Reduced Research

 
News Articles for Reduced Research top ^
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G021800-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/9/15/11G021800/amarin-1279518830220.jpg BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - September 16, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study.
Sign-up for Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study investment picks
2014/10/2
Fleet of over 100 ships will see 24 percent improvement in fuel efficiency from 2007 through 2014 Broad, multi-year strategy to conserve onboard energy usage and reduce fuel consumption will save $2.5 billion in fuel costs by the end of 2014 MIAMI , Oct.
Sign-up for Carnival Corporation Multi-Year Fuel Conservation Program Expected to Save More Than One Billion Gallons of Fuel and Reduce Carbon Emissions by 12 Billion Kilograms by End of 2014 investment picks
Neovasc Reducer™ Featured in Live Case Session at TCT 2014 Scientific Symposium Canada NewsWire Tiara™ Transcatheter Mitral Valve program featured in multiple scientific presentations NASDAQ: NVCN TSX: NVC WASHINGTON, DC , Sept.
Sign-up for Neovasc Reducer™ Featured in Live Case Session at TCT 2014 Scientific Symposium investment picks
Athens, Sept.
Sign-up for FreeSeas Concludes Sale of Vessel - Reduces Bank Debt investment picks
2014/7/24
SAN DIEGO, July 24, 2014 /PRNewswire/ -- With hot summer weather arriving in San Diego this week, San Diego Gas & Electric (SDG&E) is offering tips for residential and business customers to save energy and money now and throughout the summer.
Sign-up for SDG&E Offers Tips To Save Energy & Reduce Bills During Hot Weather investment picks
Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia Phase 3 TESLA Data Show Evolocumab Significantly Reduced LDL-C by 31 Percent Compared to Placebo in Patients With Homozygous Familial Hypercholesterolemia THOUSAND OAKS, Calif.
Sign-up for The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol investment picks
Announces Filing of Preliminary Proxy Materials for Election of Highly Qualified Slate of Directors at Darden's 2014 Annual Meeting Believes Change in Majority of Board Absolutely Required in Light of Recent, Egregious Violations of Shareholder Trust and Recent Destruction of a Billion Dollars in Shareholder Value Company's Reduced Slate is Hollow Tactic Designed to Maintain Problematic, Troubling Majority Status Quo on the Board NEW YORK , July 29, 2014 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), one of the largest shareholders of Darden Restaurants, Inc. ("Darden" or the "Company") (NYSE: DRI) , with beneficial ownership of approximately 8.1% of the outstanding common stock of the Company, today announced it has issued a statement in response to Darden's announcements that Clarence Otis will be stepping down as Chairman and Chief Executive Officer of Darden and that the Company is running a reduced slate of nine
Sign-up for Starboard Issues Statement in Response to Darden's Announced CEO Retirement and Reduced Slate at 2014 Annual Meeting investment picks
Tiara™ Transcatheter Mitral Valve program featured in multiple scientific presentations NASDAQ: NVCN TSX: NVC WASHINGTON, DC , Sept.
Sign-up for Neovasc Reducer™ Featured in Live Case Session at TCT 2014 Scientific Symposium investment picks
2014/8/14
Constellation and the Town of Essex, Mass., today announced the completion of an energy efficient lighting project designed to reduce the town’s electricity consumption by an estimated 85,266 kilowatt-hours (kWh) annually, more than 14 percent of the town’s usage.
Sign-up for Constellation Helps Town of Essex to Reduce Annual Electricity Use by 14 Percent with Energy Efficient Lighting investment picks
2014/10/9
FuturEnergy Files Revolutionary Patent Utilizing MagneGas® Fuel in Coal Co-Combustion Process Producing Energy While Reducing Greenhouse Gases TOOWOOMBA, Australia , Oct.
Sign-up for New Technology Reduces Coal Power Emissions to Natural Gas Levels and Reduces CO2 By Up To 40% investment picks
2014/10/6
Manulife Investments reduces management fees and management expense ratios (MERs) for select mutual funds and corrects MER for Manulife Floating Rate Senior Loan Fund Canada NewsWire TSX/NYSE/PSE: MFC SEHK:945 TORONTO , Oct.
Sign-up for Manulife Investments reduces management fees and management expense ratios (MERs) for select mutual funds and corrects MER for Manulife Floating Rate Senior Loan Fund investment picks
2014/8/26
Improving Patient Safety and Saving Health Care Dollars: Pharmacists Can Play Key Role in Reducing Drug Therapy Problems Canada NewsWire TORONTO , Aug.
Sign-up for Improving Patient Safety and Saving Health Care Dollars: Pharmacists Can Play Key Role in Reducing Drug Therapy Problems investment picks
Five9 (NASDAQ:FIVN), a leading provider of cloud contact center software, today announced that RJR Technology uses Five9 to reduce call back time and increase lead conversion rates for its clients.
Sign-up for RJR Technology Reduces Call Back Time and Increases Conversion Rates with Five9 investment picks
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMB r I sentan and T adalafil in patients with pulmonary arterial hypertens ION ), which was conducted in collaboration with GlaxoSmithKline (GSK). In AMBITION, first-line treatment of pulmonary arterial hypertension (PAH) with the combination of ambrisentan 10 mg and tadalafil 40 mg reduced the risk of clinical failure by 50 percent compared to the pooled ambrisentan and tadalafil monotherapy arm (hazard ratio = 0.502; 95 percent CI: 0.348, 0.724; p=0.0002). The combination was also statistically significant versus the individual ambrisentan and tadalafil monotherapy groups for the primary endpoint (p<0.01). Rates of serious adverse events and events leading to discontinuation were similar across treatment arms.
Sign-up for First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study investment picks
http://media.marketwire.com/attachments/201302/57740_wandiscoLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1142077&ProfileId=051205&sourceType=1 SAN RAMON, CA --
Sign-up for WANdisco Releases Non-Stop Hadoop 1.9.6 & Reduces Deployment Costs by 35% investment picks
2014/9/3
More than 25 million Americans, including many children, suffer from asthma and allergies, causing them to miss work or school and costing millions of dollars in healthcare expenses 1 .
Sign-up for New Study Shows Asthma & Allergy Sufferers Can Help Reduce Airborne Triggers in Their Homes by Using High-Efficiency Air Filters investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (A pixaban after the initial M anagement of P u L monary embol I sm and deep vein thrombosis with F irst-line therap Y - EXT ended Treatment). The analysis evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Results from this analysis demonstrated that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo.
Sign-up for Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) investment picks
WORCESTER, Mass., June 26, 2014 (GLOBE NEWSWIRE) -- World Energy Solutions, Inc. (Nasdaq:XWES) , a leading energy technology and services firm, today announced it has helped Catholic Health Partners (CHP) secure new electricity, natural gas and demand response contracts for all 19 of its Ohio acute-care hospitals, plus all long-term-care, integrated-care and physician-practice facilities.
Sign-up for World Energy Solutions Teams With Catholic Health Partners and American Energy Assets to Reduce Energy Costs Across Healthcare Network investment picks
Diversity in the U.S. power supply—the most cost-effective means of managing the inherent risks in fuel costs and technology performance in generating power—could be dramatically reduced in coming decades, says a new study by IHS (NYSE: IHS), the leading global source of critical information and insight.
Sign-up for IHS Study: Diversity of United States Power Supply Could be Significantly Reduced in Coming Decades investment picks
BB&T reports strong core results; Earnings reduced by mortgage and tax-related charges Canada NewsWire WINSTON-SALEM, N.C. , July 21, 2014 /CNW/ -- BB&T Corporation (NYSE: BBT) today reported second quarter 2014 net income available to common shareholders of $425 million , compared to $547 million earned in the second quarter of 2013.
Sign-up for BB&T reports strong core results; Earnings reduced by mortgage and tax-related charges investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Reduced Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Reduced Debt  |  Next: Reducing Energy